Abstract:Background: Cisplatin (DDP) is among the most widely used chemotherapeutic drugs for non-small cell lung cancer (NSCLC), yet the frequent emergence of chemoresistance serves as a major barrier to the treatment of this tumor type. Long non-coding RNAs (lncRNAs) have recently been shown to influence the ability of cells to resist particular chemotherapy drugs. The present study was developed to explore the role of the lncRNA SNHG7 as a regulator of NSCLC cell chemosensitivity. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure SNHG7 expression in NSCLC tissues from patients that were sensitive/resistant to DDP, correlations between SNHG7 expression levels and the patients' clinicopathological characteristics were assessed, and the prognostic relevance of SNHG7 expression was examined via the Kaplan-Meier approach. In addition, SNHG7 expression was assessed in NSCLC cell lines that were DDP-sensitive or -resistant, while western blotting and immunofluorescence staining were employed to detect autophagy-associated protein expression in A549, A549/DDP, HCC827, and HCC827/DDP cells. NSCLC cell chemoresistance was quantified via the Cell Counting Kit-8 (CCK-8) assay approach, and flow cytometry was used to detect the apoptotic death of these tumor cells. The chemosensitivity of xenograft tumors in vivo was further assessed to validate the functional importance of SNHG7 as a regulator of NSCLC DDP resistance. Results: Relative to paracancerous tissues, NSCLC tumors exhibited SNHG7 upregulation, and this lncRNA was further upregulated in DDP-resistant patients compared to chemosensitive patients. Consistently, higher SNHG7 expression levels were correlated with worse patient survival outcomes. DDP-resistant NSCLC cells were also found to exhibit higher levels of SNHG7 expression than chemosensitive cells, and knocking down this lncRNA enhanced the sensitivity of these cells to DDP treatment, resulting in impaired proliferation and higher rates of apoptotic death. Knocking down SNHG7 was also sufficient to suppress microtubule associated protein 1 light chain 3 beta (LC3B) and Beclin1 protein levels and promote p62 upregulation in vitro. The silencing of this lncRNA additionally inhibited the resistance of NSCLC xenograft tumors to DDP treatment in vivo. Conclusions: SNHG7 can promote malignant behaviors and DDP resistance in NSCLC cells at least partly via the induction of autophagic activity.

Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells

Skp2-Ubiquitinated MLKL Degradation Confers Cisplatin-Resistant in NSCLC Cells

Inhibition of Protein Kinase CK2 Sensitizes Non-Small Cell Lung Cancer Cells to Cisplatin Via Upregulation of PML

Overexpression of SMARCA2 or CAMK2D is Associated with Cisplatin Resistance in Human Epithelial Ovarian Cancer

Skp2 Stabilizes Mcl-1 and Confers Radioresistance in Colorectal Cancer

MLKL-PITPα signaling-mediated necroptosis contributes to cisplatin-triggered cell death in lung cancer A549 cells.

Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin

DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis

Skp2-mediated Ubiquitination and Mitochondrial Localization of Akt Drive Tumor Growth and Chemoresistance to Cisplatin.

MCL-1 is the Key Target of Adjuvant Chemotherapy to Reverse the Cisplatin-Resistance in NSCLC.

CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression

BRSK1 confers cisplatin resistance in cervical cancer cells via regulation of mitochondrial respiration

Skp2 Inhibitor AAA-237 Exerts Anti-Tumor Effect on NSCLC by Inducing Mitochondria-Dependent Apoptosis and Senescence

PDK2 induces Cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3.

MCL-1 siRNA Reverses the Chemoresistance of Cisplatin-resistant SW480 Cells via the Pathway of Mitochondrial Apoptosis

Simultaneous Targeting of ATM and Mcl-1 Increases Cisplatin Sensitivity of Cisplatin-Resistant Non-Small Cell Lung Cancer

Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2

LncRNA SNHG7 promotes non-small cell lung cancer progression and cisplatin resistance by inducing autophagic activity

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells

EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair